Tretinoin 0.045% | Hydroquinone 6%
Tretinoin 0.045% | Hydroquinone 6% is a dermatology-focused preparation for prescriber-directed skin protocols. Ingredient selection should reflect the patient's diagnosis, skin type, tolerability, pregnancy status, and treatment goal.
This compounded topical formulation combines tretinoin 0.045% with hydroquinone 6%—a two-agent depigmenting combination for moderate-to-severe hyperpigmentation. Tretinoin accelerates epidermal turnover, enhances hydroquinone penetration, and prevents post-inflammatory repigmentation, while hydroquinone directly inhibits the tyrosinase enzyme critical to melanin synthesis. The 6% hydroquinone concentration provides enhanced depigmenting activity for resistant or severe cases. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded preparation and it is not FDA-approved as a compounded product.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Tretinoin 0.045% | Retinoid that accelerates keratinocyte turnover, disperses melanin, enhances hydroquinone penetration through the stratum corneum, and reduces post-treatment repigmentation. |
| Hydroquinone 6% | Tyrosinase inhibitor that reduces melanin synthesis by blocking the enzymatic conversion of L-DOPA to melanin, selectively suppressing melanocyte pigment production. |
Applied topically once nightly to hyperpigmented areas only, on clean, dry skin. Apply a thin layer with a fingertip; avoid eyes, nostrils, and lips. Allow to absorb before applying additional products. Use daily SPF 30+ broad-spectrum sunscreen every morning—UV exposure is the primary driver of melanogenesis that both agents are attempting to suppress.
Apply a thin layer to hyperpigmented areas once nightly as directed by the prescriber. Maximum recommended duration of continuous hydroquinone use is typically 3–6 months; thereafter, the prescriber may institute a maintenance schedule or cycle therapy to minimize the risk of ochronosis. All dosing decisions are prescriber-determined.
- Tretinoin (0.045%): Activates RAR nuclear receptors in keratinocytes, increasing cell turnover to shed melanin-laden corneocytes, dispersing melanin granules, reducing tyrosinase activity, and enhancing penetration of hydroquinone through the stratum corneum. Also prevents melanocyte stimulation by blocking the AP-1 transcription factor–mediated inflammatory cascade.
- Hydroquinone (6%): A benzene metabolite structurally similar to melanin precursors (dihydroxyphenylalanine). Competitively inhibits tyrosinase, the rate-limiting enzyme in the melanin biosynthetic pathway, blocking conversion of L-DOPA to dopaquinone. Additionally causes selective cytotoxic damage to melanocytes and melanosomes at higher concentrations. Hydroquinone addresses existing epidermal melanin at the cellular production level, while tretinoin accelerates clearance of already-deposited melanin.
This combination targets moderate-to-severe melasma, severe post-inflammatory hyperpigmentation, and resistant solar lentigines where 4% hydroquinone alone is insufficient. The 6% concentration is compounded because OTC formulations are limited to 2% and prescription products are standardly 4%—higher-strength compounding addresses refractory hyperpigmentation under close prescriber supervision.
Monitoring considerations:
- Limit continuous hydroquinone use to 3–6 months; assess monthly for ochronosis (paradoxical blue-black discoloration—discontinue immediately if suspected)
- Monitor for contact sensitization or irritation
- Strict UV protection counseling is essential
- Assess for vitamin C and other antioxidant supplementation that may complement therapy
Contraindications:
- Hypersensitivity to hydroquinone, tretinoin, or any excipient
- Pregnancy (hydroquinone: Category C with significant systemic absorption; tretinoin: avoid first trimester)
- Active skin infection or dermatitis at application site
Warnings & Precautions:
- Ochronosis: rare but serious paradoxical hyperpigmentation with prolonged high-dose hydroquinone use; avoid treatment periods exceeding 3–6 months without a break
- Skin irritation: 6% hydroquinone and tretinoin together may cause significant erythema, peeling, burning; start nightly, adjust to alternate nights if intolerable
- Photosensitivity: both agents increase UV sensitivity—strict sunscreen use is mandatory
- Systemic absorption of hydroquinone (35–45%) has been reported; long-term safety profile requires monitoring
- Not for use on large body surface areas
Drug Interactions:
- Avoid concurrent oxidizing agents (benzoyl peroxide)—may inactivate tretinoin
- Avoid concurrent strong exfoliants; additive irritation
Common Side Effects: Erythema, peeling, burning, and contact dermatitis. Paradoxical hyperpigmentation (ochronosis) with extended use.
Store at room temperature (15–25°C) in opaque, sealed packaging, protected from light and air (hydroquinone oxidizes to a brown color upon prolonged air and light exposure; if discoloration is noted, discard). Do not freeze. Use within the beyond-use date assigned by Genesis Compounding.
Why is 6% hydroquinone used instead of the standard 4%?
The standard prescription-strength hydroquinone is 4%. Some cases of melasma or severe hyperpigmentation are resistant to 4% and require a higher concentration under close physician supervision. Compounding allows this individualized approach.
How long can I use this combination?
Continuous hydroquinone use is generally limited to 3–6 months due to the risk of ochronosis (paradoxical darkening). Your prescriber may recommend cycling—using the combination for several months, then taking a break or transitioning to a maintenance therapy.
What is ochronosis and how do I recognize it?
Ochronosis is a rare paradoxical skin darkening (blue-black discoloration) that can occur with prolonged high-dose hydroquinone use, particularly in darker skin types and tropical climates. If you notice worsening or unusual discoloration, contact your prescriber immediately and discontinue use.
Do I need sunscreen with this medication?
Yes—daily broad-spectrum SPF 30+ sunscreen is essential. UV exposure stimulates the exact melanin production pathways these agents are suppressing, and without sun protection the treatment will not be effective.
Is this FDA-approved?
Commercial hydroquinone 4% is available by prescription. Hydroquinone OTC products were withdrawn from the US market pending NDA review. This 6% compounded preparation is a 503A patient-specific formulation by Genesis Compounding and is not FDA-approved as a compounded product.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.